regulatory
confidence high
sentiment negative
materiality 0.50
Xenetic Biosciences receives Nasdaq minimum bid price deficiency notice
Xenetic Biosciences, Inc.
- Nasdaq notified Xenetic on June 3, 2022 that its common stock bid price was below $1.00 for 30 consecutive business days.
- Company has 180 calendar days (until November 30, 2022) to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- To cure, closing bid price must be at least $1.00 for a minimum of ten consecutive business days before the Compliance Date.
- If not cured by Nov 30, Xenetic may be eligible for a second 180-day period if it meets other listing standards and notifies Nasdaq of intention to cure, possibly via reverse stock split.
- There is no assurance the company will regain compliance; risk of delisting if deficiency is not addressed.